Table 1 Descriptive characteristics of 867 African American children with asthma included in this study
CharacteristicAfrican American
(n = 867)
Age
 Mean (SD)14.1 (3.64)
 Median (25%, 75%)13.8 (10.98, 17.11)
Sex
 Male439 (50.6%)
 Female428 (49.4%)
Height (m)
 Mean (SD)1.58 (0.145)
 Median (25%, 75%)1.60 (1.47, 1.68)
Any control medications* in last 2 weeks
 No543 (62.6%)
 Yes324 (37.4%)
ICS in last 2 weeks
 No211 (24.3%)
 Yes306 (35.3%)
 Missing350 (40.4%)
LABA in last 2 weeks
 No5 (0.6%)
 Yes94 (10.8%)
 Missing768 (88.6%)
Leukotriene inhibitor in last 2 weeks
 No11 (1.3%)
 Yes68 (7.8%)
 Missing788 (90.9%)
African ancestry
 Mean (SD)0.792 (0.129)
 Median (25%, 75%)0.826 (0.759, 0.869)
Smoking status
 Never793 (91.5%)
 Past72 (8.3%)
 Current0 (0%)
 Missing2 (0.2%)
Number of smokers in family
 0469 (54.1%)
 1137 (15.8%)
 242 (4.8%)
 3+10 (1.2%)
 Missing209 (24.1%)
SO2 first year exposure (ppb)
 Mean (SD)1.59 (0.961)
 Median (25%, 75%)1.50 (1.24, 1.87)
 Missing227 (26.2%)
SO2 past year exposure (ppb)
 Mean (SD)1.10 (0.302)
 Median (25%, 75%)1.08 (0.910, 1.27)
 Missing206 (23.8%)
SO2 lifetime exposure (ppb)
 Mean (SD)1.50 (0.371)
 Median (25%, 75%)1.47 (1.40, 1.54)
 Missing206 (23.8%)
TOPMed sequencing center and phase
 Phase 1, CAAPA6 (0.7%)
 Phase 1, NYGC460 (53.1%)
 Phase 3, NW401 (46.3%)
  • 25% and 75%, 25th and 75th percentiles. Control medications include ICS, LABA, leukotriene inhibitor, and/or ICS/LABA combo. SO2 exposures are hourly exposures averaged over the specified time periods before spirometry testing, as previously described in Neophytou et al. (2016). CAAPA, Consortium on Asthma among African-ancestry Populations in the Americas; NYGC, New York Genome Center; NW, Northwest Genomics Center; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; ppb, parts per billion or µg/m3; TOPMed, Trans-Omics for Precision Medicine.